Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double‐blind, placebo‐controlled trial
Open accessAbstract
BACKGROUND: The authors previously reported the efficacy of a dose of 4 mg of zoledronic acid in reducing skeletal complications in patients with bone metastases secondary to lung carcinoma and other solid tumors (except carcinomas of the breast and prostate). In the current study, they update these results and report the long-term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo-controlled trial. METHODS: A total of 773 patients were randomized to receive zoledronic acid (4 mg or 8 mg) or placebo via a 15-minute infusion every 3 weeks for 21 months. The 8-mg dose later was reduced to 4 mg (8/4-mg group). The primary efficacy endpoint was the percentage of patients at 21 months with >/= 1 skeletal-related event (SRE) (pathologic fracture, spinal cord compression, radiation therapy to bone, or surgery to bone). Secondary analyses (time to first SRE, annual incidence of SREs, and multiple-event analysis) included hypercalcemia of malignancy. RESULTS: Fewer patients treated with zoledronic acid developed at least 1 SRE at 21 months compared with patients treated with placebo (39% of those treated at the 4-mg dose [P =0.127] and 36% of those treated at the 8/4-mg dose [P = 0.023], compared with 46% of those treated with placebo). Furthermore, 4 mg of zoledronic acid significantly delayed the median time to first SRE (236 days with 4 mg vs. 155 days with placebo; P = 0.009) and significantly reduced the annual incidence of SREs (1.74 per year with the 4-mg dose vs. 2.71 per year with placebo; P = 0.012). Moreover, the 4-mg dose of zoledronic acid was found to reduce the risk of developing a skeletal event by 31% (hazard ratio of 0.693; P = 0.003). Zoledronic acid was found to be well tolerated with long-term use; the most commonly reported adverse events in all treatment groups included bone pain and the transient, acute-phase reactions of nausea, anemia, and emesis. CONCLUSIONS: To the authors' knowledge, zoledronic acid is the first bisphosphonate to demonstrate long-term safety and efficacy in this patient population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Zoledronic acid reduces skeletal-related events, including pathological fracture, radiation or surgery to bone, and spinal cord compression.
“Zoledronic acid reduces skeletal-related events (SREs) ( pathological fracture, radiation or surgery to bone, or spinal cord compression) and is recommended in stage IV bone metastatic disease [II,B] [160].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419 · see citing works
Fred Saad, C., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P. N., Lacombe, L., Chin, J. L., Vinholes, J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,654 · see citing works
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896 · see citing works
Self-citationMalignant bone pain: pathophysiology and treatment
Mercadante, S. (1997) · Pain · doi:10.1016/s0304-3959(96)03267-8 · Cited by 861 · see citing works
Major, P. P., Lortholary, A. H., Hon, J. K., Abdi, E. A., Mills, G. M., Menssen, H. D., Yunus, F., Bell, R., Body, J. J., Quebe‐Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 844 · see citing works
Self-citationRosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R. H., Hirsh, V., Krzakowski, M. J., Pawlicki, M., SOUZA, P. D., Zheng, M., Urbanowitz, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.105 · Cited by 728 · see citing works
Self-citationPittas, A. G., Adler, M., Fazzari, M. J., Tickoo, S. K., Rosaí, J., Larson, S. M., & Robbins, R. J. (2000) · Thyroid · doi:10.1089/thy.2000.10.261 · Cited by 222 · see citing works
The skeletal metastatic complications of renal cell carcinoma
Zekri, J., Ahmed, N., Coleman, R., et al. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.379 · Cited by 204 · see citing works
Radiologic diagnosis of bone metastases
Rosenthal, D. I. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+ · Cited by 186 · see citing works
The clinical use of bone resorption markers in patients with malignant bone disease
Coleman, R. E. (2002) · Cancer · doi:10.1002/cncr.10522 · Cited by 92 · see citing works
Metastatic bone disease from occult carcinoma: a profile
Nottebaert, M., Exner, G. U., Hochstetter, A. R. V., et al. (1989) · International Orthopaedics · doi:10.1007/bf00266372 · Cited by 76 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644 · see citing works
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151 · see citing works
Scagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., Solal-Celigny, P., Rodriguez, G., Krzakowski, M., Mehta, N. D., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aec2b · Cited by 335 · see citing works
Self-citationSafety of intravenous and oral bisphosphonates and compliance with dosing regimens
Conte, P., & Guarneri, V. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-28 · Cited by 241 · see citing works
Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-013-2022-1 · Cited by 183 · see citing works
- Authors
- Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., Reitsma, D., Seaman, J., & On behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
- Affiliations
- McGill University Health Centre (CA)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Novartis (United States) (US)
- Corresponding author
- Rosen, Lee S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-06-02
- Volume
- 100
- Issue
- 12
- Pages
- 2613-2621
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1996589664
- Cited by
- 705
- References
- 11
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 21 · 2023: 22 · 2022: 29 · 2021: 22 · 2020: 36 · 2019: 29 · 2018: 24 · 2017: 29 · 2016: 33 · 2015: 39 · 2014: 38 · 2013: 40 · 2012: 52
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- zoledronic acid, bisphosphonates, bone metastasis, skeletal-related events, non-small cell lung cancer, solid tumors, hypercalcemia of malignancy, pathological fracture, spinal cord compression, long-term safety, dose comparison, bone pain, anemia, nausea, vomiting, treatment discontinuation
- MeSH terms
- Zoledronic Acid, Antineoplastic Agents, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Diphosphonates, Double-Blind Method, Humans, Imidazoles, Lung Neoplasms, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
